/PRNewswire/ Key takeaways Projected return on investment in pharma research and development (R&D) in 2023 has risen to 4.1%, climbing back from 2022 s.
A pair of recently-released studies shed new light on the staggering cost of developing new drugs an expense that now exceeds $2 billion per therapy on average.
Plus: Exclusive: Quest Diagnostics to acquire New York-Presbyterian lab services this year Good Samaritan University Hospital unveils new $8.5M Mother Baby unit Martin Shkreli’s two new companies thread the needle between pharma and tech
/PRNewswire/ Key takeaways Projected returns on investment (ROI) in pharma R&D in 2022 have fallen to 1.2%, the lowest ROI observed in the 13 years since.